# 5 Prime Capping: Mechanism, Function, and Significance in mRNA ## Introduction to 5 Prime Capping 5 prime capping is the co-transcriptional modification of the 5' end of eukaryotic messenger RNA (mRNA), wherein a 7-methylguanosine nucleotide is attached to the first transcribed nucleotide via an inverted 5'-5' triphosphate linkage. This modification occurs on virtually all [RNA polymerase](/knowledge/bioinformatics/rna-polymerase-structure-transcription-mechanisms) II (Pol II) transcripts, including mRNA and many long non-coding RNAs, and is the first of three major [mRNA processing](/knowledge/molecular-biology/mrna-processing) events—the others being [mRNA Splicing](/knowledge/molecular-biology/mrna-splicing) and 3' end cleavage and polyadenylation. The cap was first identified in the late 1970s through studies of vesicular stomatitis virus (VSV) mRNAs, which revealed an unusual 5'-5' linkage resistant to conventional 5'→3' exonuclease digestion. Subsequent work by Aaron Shatkin and colleagues established that the cap structure is ubiquitous across eukaryotic mRNAs and plays essential roles in nearly every stage of mRNA metabolism, from transcription to translation and decay. The fundamental importance of capping cannot be overstated. It protects the nascent transcript from degradation by 5'→3' exonucleases, promotes efficient splicing of the first intron, facilitates nuclear export, and is required for efficient translation initiation. Without capping, eukaryotic mRNAs are rapidly degraded and never reach the ribosome. This article details the structure, biosynthesis, functions, and experimental analysis of the 5' cap, with attention to mechanistic detail and organismal variation. ## The 5' Cap Structure: m7G and Beyond The canonical 5' cap consists of a 7-methylguanosine (m7G) linked to the 5' phosphate of the first transcribed nucleotide through a 5'-5' triphosphate bridge. This inverted linkage is unique in nucleic acid chemistry: the guanosine is oriented in the opposite direction relative to the RNA chain, with its 3' hydroxyl free and its 5' hydroxyl participating in the triphosphate bridge. The N7 position of the guanine base carries a methyl group, giving the structure its characteristic positive charge under physiological conditions. The complete cap structure is written as m7G(5')ppp(5')N, where N is the first transcribed nucleotide. The triphosphate bridge contains three phosphate groups: the α-phosphate is derived from the incoming GTP, while the β and γ phosphates originate from the 5' triphosphate of the first transcribed nucleotide. This arrangement is critical for recognition by cap-binding proteins and for resistance to 5'→3' exonucleases, which require a monophosphate at the 5' end to initiate processive degradation. Beyond the core m7G cap, additional methylations can occur on the first and second transcribed nucleotides, generating cap 1 and cap 2 structures. These modifications are catalyzed by distinct methyltransferases and have important functional consequences for innate immune recognition and mRNA stability. ### Cap 0, Cap 1, and Cap 2 The simplest cap structure, found in yeast and some viral mRNAs, is termed cap 0: m7G(5')ppp(5')N. In higher eukaryotes, the ribose of the first transcribed nucleotide is additionally methylated at the 2'-O position, producing cap 1: m7G(5')ppp(5')Nm. Cap 2, which contains 2'-O-methylation on both the first and second transcribed nucleotides, is found on a subset of mRNAs in metazoans. The distinction between cap 0 and cap 1 has profound biological significance. The cytoplasmic innate immune sensors RIG-I (retinoic acid-inducible gene I) and MDA5 (melanoma differentiation-associated protein 5) distinguish self from non-self RNA partly by cap status. Cap 0 RNAs are recognized as foreign and trigger interferon responses, whereas cap 1 structures are largely invisible to these sensors. This is why many viruses that replicate in the cytoplasm have evolved mechanisms to produce cap 1 structures, either by encoding their own capping enzymes or by stealing caps from host mRNAs. ## The Capping Process: Step-by-Step Mechanism Capping occurs co-transcriptionally, when the nascent RNA chain is only 20–30 nucleotides long. The process is catalyzed by a tripartite enzyme complex that associates with the C-terminal domain (CTD) of RNA polymerase II. The three enzymatic activities—RNA triphosphatase, guanylyltransferase, and N7-methyltransferase—act in a strictly ordered sequence. ### Step 1: Removal of the γ-phosphate The first step is catalyzed by RNA 5'-triphosphatase, which removes the γ-phosphate from the 5' end of the nascent transcript. The substrate is the 5' triphosphate (pppN) of the first transcribed nucleotide, and the product is a 5' diphosphate (ppN). This reaction requires a divalent metal ion, typically Mg²⁺, and proceeds through a phosphoenzyme intermediate in some enzymes or via direct hydrolysis in others. In metazoans, the triphosphatase activity resides in a separate polypeptide (e.g., human DCP2-associated triphosphatase, or the N-terminal domain of the bifunctional capping enzyme in some organisms). In yeast, the triphosphatase (Cet1) is a distinct protein that forms a complex with the guanylyltransferase (Ceg1). The reaction is essentially irreversible under physiological conditions, with a large negative free energy change driven by phosphate release. ### Step 2: Addition of GMP The second step is catalyzed by mRNA guanylyltransferase (GTase), which transfers GMP from GTP to the 5' diphosphate end of the RNA. The reaction proceeds through a covalent enzyme-GMP intermediate: the GTase attacks the α-phosphate of GTP, releasing pyrophosphate and forming a phosphoamide linkage to a conserved lysine residue in the active site. The enzyme-GMP intermediate then transfers GMP to the 5' diphosphate of the RNA, forming the characteristic 5'-5' triphosphate bridge. This reaction is highly specific for the 5' diphosphate substrate; RNA with a 5' triphosphate is not a substrate. The GTase therefore acts after the triphosphatase and before the methyltransferase. The human GTase is a bifunctional enzyme (encoded by RNGTT) that also contains the triphosphatase domain in its N-terminal region. The reaction requires Mg²⁺ or Mn²⁺ and GTP as the guanine nucleotide donor. ### Step 3: Methylation at N7 The final step is the methylation of the N7 position of the newly added guanine, catalyzed by mRNA (guanine-N7)-methyltransferase. The methyl donor is S-adenosylmethionine (SAM), which is converted to S-adenosylhomocysteine (SAH) during the reaction. The methyltransferase recognizes the GpppN structure and methylates the guanine N7 position, producing m7GpppN. This methylation is essential for cap function. The m7G cap is recognized by the nuclear cap-binding complex (CBC) and the cytoplasmic translation initiation factor eIF4E, both of which bind specifically to the methylated form. Unmethylated GpppN is not recognized by these factors and does not protect RNA from degradation. In yeast, the N7-methyltransferase (Abd1) is a separate enzyme, while in metazoans it is a domain of the bifunctional capping enzyme. The complete capping reaction can be summarized as: pppNpNp... → ppNpNp... → GpppNpNp... → m7GpppNpNp... All three steps occur in the nucleus, tightly coupled to transcription. The capping enzymes are recruited to the Pol II CTD when it is phosphorylated at serine 5, which occurs during [transcription initiation](/knowledge/molecular-biology/transcription-initiation) and early elongation. ## Enzymes and Machinery Involved in Capping The capping machinery is organized around the C-terminal domain of the largest subunit of RNA polymerase II. The CTD consists of tandem heptapeptide repeats with the consensus sequence YSPTSPS—26 repeats in yeast, 52 in mammals. Phosphorylation of serine 5 (Ser5) by the kinase CDK7 (part of the TFIIH complex) creates a docking site for the capping enzyme. ### Capping enzyme and CTD interaction The capping enzyme binds specifically to the Ser5-phosphorylated CTD through a conserved domain. In yeast, the guanylyltransferase Ceg1 binds to the phosphorylated CTD via its C-terminal region, while the triphosphatase Cet1 is recruited through interaction with Ceg1. In metazoans, the bifunctional capping enzyme (containing both triphosphatase and guanylyltransferase activities) binds directly to the Ser5-phosphorylated CTD. This physical coupling ensures that capping occurs before the nascent RNA reaches a length where it could be degraded or misfolded. The CTD acts as a processivity platform, positioning the capping enzyme near the RNA exit channel of Pol II. As the polymerase transcribes, the emerging 5' end of the RNA is immediately available for capping. The N7-methyltransferase is also recruited to the transcription complex, though its association with the CTD is less well characterized. In yeast, Abd1 is recruited through interaction with the elongation factor Spt5, while in mammals, the methyltransferase is part of the capping enzyme complex or recruited independently. The coupling of capping to transcription has important regulatory consequences. The rate of capping can influence transcriptional elongation, and defects in capping lead to premature [transcription termination](/knowledge/molecular-biology/transcription-terminated) and degradation of the nascent RNA by the exosome. This quality control mechanism ensures that only properly capped transcripts are processed further. ## Functions of the 5' Cap in mRNA Metabolism The 5' cap serves multiple essential functions throughout the life of an mRNA. These functions are mediated by specific cap-binding proteins that recognize the m7G structure and recruit downstream effectors. ### Protection from 5'→3' exonucleases The most fundamental function of the cap is to protect mRNA from 5'→3' exonucleolytic degradation. The major 5'→3' exonuclease in eukaryotic cells, XRN1, requires a 5' monophosphate to initiate processive degradation. The cap structure, with its 5'-5' linkage and methylated guanine, is not a substrate for XRN1, effectively blocking this decay pathway. The protective function of the cap is not passive, however. The nuclear cap-binding complex (CBC), composed of CBP80 and CBP20, binds the cap immediately after capping and protects the RNA during splicing and nuclear export. In the cytoplasm, the cap is bound by eIF4E, which also protects the 5' end from exonucleases. When the cap is removed by decapping enzymes (DCP2 and its cofactors), the mRNA becomes susceptible to XRN1-mediated degradation. The half-life of an mRNA is therefore determined in part by the stability of its cap. mRNAs with more stable caps, or those that are more efficiently re-capped after decapping, tend to be more stable. The balance between capping and decapping is a major control point in [gene expression](/blog/guides/gene-expression). ### Enhancement of translation The cap is essential for efficient translation initiation. The cytoplasmic cap-binding protein eIF4E recognizes the m7G cap and recruits eIF4G and eIF4A to form the eIF4F complex. eIF4G then interacts with the 40S ribosomal subunit (via eIF3) and the poly(A)-binding protein (PABP), circularizing the mRNA and promoting ribosome recruitment. The affinity of eIF4E for the cap is highly specific: it binds m7GpppN with a dissociation constant (Kd) of approximately 0.1–1 μM, but shows negligible binding to unmethylated GpppN or to caps with altered methylation patterns. This specificity ensures that only properly capped mRNAs are translated. The cap-dependent translation initiation pathway is the target of extensive regulation. The eIF4E-binding proteins (4E-BPs) compete with eIF4G for binding to eIF4E, inhibiting translation when phosphorylated by mTOR. Many viruses that infect eukaryotic cells have evolved strategies to either cap their own mRNAs or bypass the requirement for cap-dependent translation, often by encoding internal ribosome entry sites (IRESs) or by cleaving eIF4G. ## Capping in Different Organisms and Viruses While the m7G cap is conserved across eukaryotes, there is significant variation in capping mechanisms among different organisms and viruses. Some bacteria, particularly those in the phylum Bacteroidetes, have recently been found to cap their mRNAs with a nicotinamide adenine dinucleotide (NAD) or related compounds, though this is distinct from the eukaryotic m7G cap. ### Viral cap snatching and cap synthesis Viruses have evolved diverse strategies to obtain caps for their mRNAs. Negative-strand RNA viruses, such as influenza virus, use a process called cap snatching: the viral polymerase binds the host mRNA cap, cleaves the RNA 10–15 nucleotides downstream, and uses the capped fragment as a primer for viral transcription. This strategy allows the virus to acquire a cap 1 structure without encoding its own capping enzymes. Other viruses encode their own capping enzymes. The vaccinia virus (a poxvirus) encodes a bifunctional capping enzyme with both triphosphatase and guanylyltransferase activities, as well as a separate methyltransferase. These enzymes cap viral mRNAs in the cytoplasm, where the virus replicates, independent of the nuclear capping machinery. Coronaviruses, including SARS-CoV-2, encode a complex capping machinery that produces cap 1 structures. The nonstructural protein nsp14 has both 3'-5' exoribonuclease and N7-methyltransferase activities, while nsp16, in complex with nsp10, provides the 2'-O-methyltransferase activity. The production of cap 1 structures is essential for these viruses to evade RIG-I-mediated innate immune recognition. Some viruses, such as picornaviruses, do not have caps on their mRNAs at all. Instead, they use an internal ribosome entry site (IRES) to initiate translation in a cap-independent manner. These viruses are not subject to cap-dependent regulation and can shut off host [protein synthesis](/blog/guides/protein-synthesis-a-step-by-step-guide-to-transcription-and-translation) by cleaving eIF4G. ## Methods to Study 5' Capping Several experimental approaches are used to study the 5' cap, ranging from biochemical characterization to high-throughput sequencing. ### Cap-specific immunoprecipitation Antibodies that specifically recognize the m7G cap can be used to immunoprecipitate capped RNAs. The most commonly used antibody, H20, recognizes m7G caps with high specificity and can be used to enrich capped mRNAs from total RNA. This approach is often combined with RNA sequencing to identify capped transcripts and map their 5' ends. Cap-specific immunoprecipitation is also used to study cap dynamics, such as the exchange of nuclear CBC for cytoplasmic eIF4E, or to identify RNAs that are subject to decapping and recapping. ### Cap analysis [gene expression](/blog/guides/gene-expression) (CAGE) CAGE is a high-throughput method that maps transcription start sites (TSSs) at single-nucleotide resolution by sequencing the 5' ends of capped mRNAs. The method involves capturing capped RNAs, converting the cap to a specific adapter sequence, and sequencing the first 20–30 nucleotides of each transcript. CAGE has been used extensively to create promoter atlases for various organisms and cell types, revealing the complexity of [transcription initiation](/knowledge/molecular-biology/transcription-initiation) and the diversity of promoter architectures. The technique can also detect alternative TSS usage and identify novel transcripts. Mass spectrometry is used to characterize cap structures in detail, including the methylation status of the cap and the first transcribed nucleotides. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can distinguish cap 0, cap 1, and cap 2 structures and quantify their relative abundances. ## Clinical Relevance and Applications of Capping Defects in capping are associated with several human diseases. Mutations in the capping enzyme genes can cause developmental disorders, and dysregulation of capping has been implicated in cancer. The cap and its binding proteins are also targets for therapeutic intervention. ### mRNA vaccines and cap analogs The most prominent clinical application of capping is in mRNA therapeutics, particularly vaccines. The mRNA vaccines for COVID-19 (from Pfizer-BioNTech and Moderna) use in vitro transcribed mRNA that is capped during synthesis. The cap is essential for the mRNA to be translated efficiently in vivo and to avoid triggering innate immune responses. The capping of in vitro transcribed mRNA is achieved using vaccinia virus capping enzyme, which adds a cap 0 structure. However, cap 0 structures can still trigger innate immune responses through RIG-I. To address this, mRNA vaccines use cap analogs that incorporate 2'-O-methylation on the first transcribed nucleotide, producing cap 1 structures that are more translationally active and less immunostimulatory. Cap analogs are synthetic molecules that mimic the cap structure and can be incorporated during in vitro transcription. The most commonly used cap analogs are anti-reverse cap analogs (ARCA), which have a modified 3' position on the m7G that prevents incorporation in the reverse orientation. Newer cap analogs, such as CleanCap, incorporate the 2'-O-methylation during synthesis, producing cap 1 structures in a single step. The success of mRNA vaccines has accelerated research into mRNA therapeutics for other applications, including protein replacement therapy, cancer immunotherapy, and gene editing. The cap is a critical component of all these approaches, and optimizing cap structure and capping efficiency is an active area of research. ## Common Pitfalls and Misconceptions in Understanding 5' Capping Students frequently encounter several conceptual difficulties when learning about 5' capping. **Confusing capping with polyadenylation.** Capping occurs at the 5' end, polyadenylation at the 3' end. They are mechanistically distinct, catalyzed by different enzymes, and serve different functions. Capping protects the 5' end and promotes translation; polyadenylation protects the 3' end and promotes translation and stability. They are not interchangeable. **Misunderstanding the directionality of the cap linkage.** The cap is linked 5'-to-5', not 5'-to-3'. This inverted linkage is what makes the cap resistant to 5'→3' exonucleases and gives it its unique chemical properties. Students often draw the cap as a conventional 5'-3' linkage, which is incorrect. **Thinking capping occurs in the cytoplasm.** Capping is a nuclear, co-transcriptional process. It occurs when the nascent RNA is only 20–30 nucleotides long, before splicing and export. Cytoplasmic recapping exists but is a minor pathway. **Assuming all RNA is capped.** Only RNA polymerase II transcripts are capped. Ribosomal RNA (rRNA), transfer RNA (tRNA), and other Pol I and Pol III transcripts are not capped. Additionally, some mRNAs can be decapped in the cytoplasm and are not recapped. **Confusing cap 0 and cap 1.** Cap 0 has only the m7G methylation; cap 1 has additional 2'-O-methylation on the first transcribed nucleotide. This distinction is functionally important for innate immune recognition. **Overlooking the triphosphate bridge.** The 5'-5' triphosphate linkage is essential for cap function. It is not simply a methylated guanine attached to the RNA; the triphosphate bridge is part of the recognition motif for cap-binding proteins. ## Frequently Asked Questions ### What is 5 prime capping? 5 prime capping is the co-transcriptional modification of the 5' end of eukaryotic mRNA, in which a 7-methylguanosine is attached to the first transcribed nucleotide via a 5'-5' triphosphate linkage. It is the first mRNA processing event and is essential for mRNA stability, export, and translation. ### What are the steps of 5 prime capping? Capping occurs in three enzymatic steps: (1) removal of the γ-phosphate from the 5' end by RNA triphosphatase, (2) transfer of GMP from GTP to the 5' diphosphate by guanylyltransferase, and (3) methylation of the N7 position of guanine by N7-methyltransferase using SAM as the methyl donor. ### Where does 5 prime capping occur? Capping occurs in the nucleus, co-transcriptionally. The capping enzymes are recruited to the C-terminal domain of RNA polymerase II when it is phosphorylated at serine 5, and capping occurs when the nascent RNA is only 20–30 nucleotides long. ### Why is the 5' cap important? The 5' cap protects mRNA from 5'→3' exonucleolytic degradation, promotes splicing of the first intron, facilitates nuclear export, and is required for efficient translation initiation through recognition by eIF4E. It also distinguishes self RNA from foreign RNA in innate immune recognition. ### What is the structure of the 5' cap? The cap is 7-methylguanosine linked to the first transcribed nucleotide through a 5'-5' triphosphate bridge (m7G(5')ppp(5')N). Additional methylations on the first and second transcribed nucleotides produce cap 1 and cap 2 structures. ### How is 5 prime capping studied? Capping is studied using cap-specific antibodies for immunoprecipitation, CAGE (cap analysis gene expression) for mapping transcription start sites, mass spectrometry for detailed cap structure analysis, and in vitro capping assays with recombinant enzymes. ### What is the difference between cap 0 and cap 1? Cap 0 has only the m7G methylation on the terminal guanine. Cap 1 has an additional 2'-O-methylation on the ribose of the first transcribed nucleotide. Cap 1 is important for evading innate immune recognition by RIG-I and is the standard for mRNA therapeutics. ## Key Takeaways - The 5' cap is a 7-methylguanosine linked to the first transcribed nucleotide via a 5'-5' triphosphate bridge, added co-transcriptionally to all RNA polymerase II transcripts. - Capping occurs in three ordered enzymatic steps—triphosphatase, guanylyltransferase, and N7-methyltransferase—catalyzed by enzymes recruited to the Ser5-phosphorylated CTD of RNA polymerase II. - The cap protects mRNA from 5'→3' exonucleases, promotes splicing and nuclear export, and is required for efficient translation initiation via eIF4E binding. - Cap 0 and cap 1 structures differ in 2'-O-methylation of the first transcribed nucleotide, with cap 1 being critical for evading RIG-I-mediated innate immune detection. - Viruses have evolved diverse capping strategies, including cap snatching (influenza) and self-encoded capping enzymes (vaccinia, coronaviruses). - Capping is studied using cap-specific antibodies, CAGE, and mass spectrometry, and is a critical component of mRNA vaccines and therapeutics. - Capping is distinct from polyadenylation, occurs in the nucleus, and is specific to Pol II transcripts—common points of confusion for students. ## Related Topics - [5 Prime Cap](/knowledge/molecular-biology/5-prime-cap) - [Prime Capital Product](/knowledge/molecular-biology/prime-capital-product) - [Introns Exons](/knowledge/molecular-biology/introns-exons) - [Transcription Factor](/knowledge/molecular-biology/transcription-factor) - [Transcription Termination](/knowledge/molecular-biology/transcription-termination) ## Related Clinical & Scientific Guides * [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway) * [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor) * [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)